The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ANIX | +23.64% | -28.31% | -6.43% | -93% |
| S&P | +16.89% | +84.17% | +12.98% | +4,292% |
Anixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. It operates through the following segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics, and Patent Licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
No news articles found for Anixa Biosciences.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$9.00K | 0.0% |
| Market Cap | $135.95M | 20.7% |
| Market Cap / Employee | $33.99M | 0.0% |
| Employees | 4 | -20.0% |
| Net Income | -$2,722.00K | 6.6% |
| EBITDA | -$2,867.00K | 9.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.24M | -2.1% |
| Accounts Receivable | $0.00K | -100.0% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $163.00K | -19.7% |
| Short Term Debt | $41.00K | 41.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -58.01% | -4.7% |
| Return On Invested Capital | -59.89% | 32.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,255.00K | -35.4% |
| Operating Free Cash Flow | -$1,255.00K | -35.4% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.67 | 5.03 | 6.13 | 8.17 | 58.06% |
| Price to Sales | 679.83 | - | |||
| Price to Tangible Book Value | 4.67 | 5.03 | 6.13 | 8.17 | 58.06% |
| Enterprise Value to EBITDA | -22.27 | -24.48 | -33.94 | -41.91 | 43.87% |
| Return on Equity | -58.8% | -61.1% | -57.9% | -62.2% | 9.76% |
| Total Debt | $230.00K | $221.00K | $213.00K | $204.00K | -12.07% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
